Carnitine Deficiency Due to Inborn Errors of Metabolism (ICD-10-CM Code: E71.42)

Name of the Condition

• Carnitine deficiency due to inborn errors of metabolism.

Summary

Carnitine deficiency due to inborn errors of metabolism refers to conditions where genetic defects disrupt carnitine synthesis, transport, or utilization, impairing fatty acid metabolism and energy production. Carnitine is essential for converting fats into energy, particularly in tissues like the heart and muscles. These disorders may lead to systemic complications if untreated, as they affect cellular energy processes.

Causes

These deficiencies are caused by genetic mutations affecting enzymes or transporters involved in carnitine metabolism. Inherited in an autosomal recessive pattern, they require mutations in both copies of the relevant gene for clinical manifestation. The specific genetic defect determines the subtype and severity of the deficiency.

Risk Factors

• Family history of carnitine metabolism disorders.
• Consanguinity (parents who are closely related).
• Certain ethnic populations with higher carrier rates for specific mutations.

Symptoms

• Muscle weakness or fatigue.
• Hypotonia (reduced muscle tone).
• Cardiomyopathy (heart muscle disease).
• Recurrent hypoglycemia (low blood sugar).
• Developmental delay or regression.
• Metabolic crises, including hypoketotic hypoglycemia.

Diagnosis

Diagnosis involves biochemical testing to measure carnitine levels in blood or urine, often revealing deficiencies or abnormal ratios. Confirmatory testing may include genetic analysis to identify the specific inborn error. Clinical evaluation assesses symptoms and family history to support the diagnosis.

Treatment Options

Treatment typically includes carnitine supplementation to restore levels and support metabolic function. Dietary modifications may be recommended to manage energy needs. In some cases, additional therapies target specific symptoms, such as managing hypoglycemia or cardiac complications. Regular monitoring is essential to adjust treatment as needed.

Prognosis and Follow-Up

Prognosis depends on the severity of the deficiency and timeliness of treatment. Early intervention with carnitine supplementation can improve outcomes, but untreated cases may lead to progressive muscle or cardiac damage. Long-term follow-up is necessary to monitor for complications and adjust therapy.

Complications

• Progressive muscle weakness or atrophy.
• Worsening cardiomyopathy or heart failure.
• Recurrent metabolic crises.
• Developmental delays or regression if untreated.
• Increased risk of hypoglycemia or other metabolic imbalances.

Lifestyle & Prevention

• Adherence to prescribed carnitine supplementation and dietary guidelines.
• Regular physical activity, as tolerated, to maintain muscle function.
• Avoidance of prolonged fasting or strenuous exercise that may trigger metabolic crises.
• Genetic counseling for families with a history of the condition.

When to Seek Professional Help

Seek medical attention if symptoms such as severe muscle weakness, chest pain, or recurrent hypoglycemia occur. Prompt evaluation is critical to prevent complications. Follow up with a healthcare provider regularly to monitor treatment effectiveness and adjust care plans.

Tips for Medical Coders

When coding for E71.42, ensure documentation specifies the inborn error of metabolism causing the carnitine deficiency. Include details about genetic testing, biochemical results, or clinical findings that confirm the diagnosis. Avoid using this code for unspecified or secondary carnitine deficiencies; use the appropriate code for those scenarios. Verify that the documentation supports the link between the inborn error and the deficiency to justify the code assignment.